Warning letter
Pinnacle Labs International, Inc.: warning letter of Jun 19, 2014
FDA warning letter 397702 · Los Angeles District Office
Key facts
| Reference number | 397702 |
|---|---|
| Company | Pinnacle Labs International, Inc. |
| Subject | CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Jun 19, 2014 |
| Posted date | Jul 15, 2014 |
| Issuing office | Los Angeles District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 101.5, 111, 111.75, 111.260, 101.3(g), 101.4(h)(1), 111.75(a)(2)(ii), 111.260(b), 111.260(d), 111.260(f), 111.260(j), 111.260(j)(2)(i) and 11 more |
| Inspection city | Upland |
| Inspection ZIP | 91786 |
| Inspection start date | Apr 11, 2013 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: